Genetic
ADI-001
ADI-001 is a genetic therapy with 4 clinical trials. Currently 2 active trials ongoing.
Total Trials
4
Max Phase
—
Type
GENETIC
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
2(50%)
Terminated
1(25%)
Phase Distribution
Ph phase_1
3
75%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Terminated(1)
Detailed Status
Enrolling by invitation1
Active, not recruiting1
Recruiting1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
0.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
enrolling_by_invitation125%
active_not_recruiting125%
recruiting125%
terminated125%
Recent Activity
2 active trials
Showing 4 of 4
active_not_recruiting
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
NCT04911478
enrolling_by_invitationphase_1
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
NCT06375993
recruitingphase_1
A Phase 1 Study of ADI-001 in Rheumatoid Arthritis
NCT07100873
terminatedphase_1
A Phase 1 Study of ADI-001 in B Cell Malignancies
NCT04735471
Clinical Trials (4)
Showing 4 of 4 trials
NCT04911478
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
NCT06375993Phase 1
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
NCT07100873Phase 1
A Phase 1 Study of ADI-001 in Rheumatoid Arthritis
NCT04735471Phase 1
A Phase 1 Study of ADI-001 in B Cell Malignancies
All 4 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 4